Does TRICARE Cover Rezdiffra (Resmetirom)?

TRICARE Formulary Status for Rezdiffra

Rezdiffra (resmetirom) is listed on the TRICARE formulary as a specialty-tier medication. It is not available as a preferred brand, which means out-of-pocket costs are higher than drugs on the preferred formulary tier, and prior authorization is required before TRICARE will pay for it.

TRICARE's Pharmacy Operations Directorate, managed through Express Scripts, classifies specialty drugs based on therapeutic category, cost, and clinical evidence thresholds. Rezdiffra's classification reflects its status as the first FDA-approved oral therapy specifically indicated for MASH with moderate-to-advanced hepatic fibrosis. The FDA granted accelerated approval in March 2024 based on surrogate endpoints of MASH resolution and fibrosis improvement [1]. Because the approval used a surrogate endpoint rather than long-term clinical outcomes like cirrhosis prevention, some payers, including TRICARE, apply tighter utilization management controls.

TRICARE beneficiaries using the mail-order pharmacy through Express Scripts will generally face the specialty copay tier. For TRICARE Prime enrollees, specialty copays can reach $60 or more per prescription fill depending on the specific plan. TRICARE For Life beneficiaries with Medicare Part D as primary coverage follow a different cost-sharing structure entirely. Confirming your specific plan's cost-sharing schedule through the TRICARE formulary search tool before requesting the prescription is a practical first step [2].

Prior Authorization Requirements

Getting Rezdiffra approved through TRICARE prior authorization requires moderate effort. The prescribing provider must submit clinical documentation supporting the MASH diagnosis and fibrosis staging.

Standard criteria that TRICARE reviewers evaluate include a confirmed diagnosis of MASH (previously called nonalcoholic steatohepatitis or NASH), hepatic fibrosis staged at F2 or F3 by liver biopsy or validated noninvasive markers such as FibroScan (vibration-controlled transient elastography) or the Enhanced Liver Fibrosis (ELF) test, evidence that the patient has attempted lifestyle modifications including dietary changes and exercise, and prescribing by or in consultation with a hepatologist or gastroenterologist. TRICARE aligns many of its specialty drug criteria with the American Association for the Study of Liver Diseases (AASLD) practice guidance, which recommends pharmacotherapy for patients with biopsy-confirmed NASH and significant fibrosis (F ≥ 2) [3].

The prior authorization form is submitted electronically by the prescriber's office through the Express Scripts provider portal. Turnaround time for standard requests is typically 5 to 10 business days. Urgent requests, when clinically justified, can be processed in 24 to 72 hours.

A common reason for initial denial is insufficient fibrosis documentation. Providers should include the actual FibroScan kPa value or biopsy report rather than a summary statement. Including the patient's FIB-4 index score alongside the primary staging method strengthens the submission.

Step Therapy and Clinical Criteria

TRICARE may apply step therapy requirements before approving Rezdiffra, consistent with evidence-based treatment sequencing for MASH.

Step therapy for MASH drugs on TRICARE typically requires documentation that the patient has tried or cannot tolerate first-line interventions. For MASH specifically, these include structured lifestyle modification (caloric restriction and at least 150 minutes per week of moderate-intensity exercise) sustained over a minimum of 6 months, and consideration of vitamin E (800 IU daily) for non-diabetic patients with biopsy-proven NASH, as supported by the PIVENS trial [4]. The PIVENS trial (N=247) demonstrated that vitamin E 800 IU daily for 96 weeks produced NASH resolution in 36% of patients compared to 21% on placebo (P=0.005), establishing it as a reference comparator in the treatment pathway [4].

Patients with type 2 diabetes may also need documentation showing that pioglitazone was considered, given its evidence base in NASH resolution from the same trial. TRICARE reviewers look for a reason pioglitazone was not used (contraindication, intolerance, or clinical unsuitability) before waiving this step.

The practical approach: have the prescriber's prior authorization letter explicitly state each step therapy criterion, what was tried, and why Rezdiffra is now clinically appropriate. A single-page clinical summary letter that walks through the step therapy checklist significantly reduces back-and-forth with reviewers.

MAESTRO-NASH Trial Evidence Supporting Coverage

The clinical evidence supporting Rezdiffra's approval comes primarily from the MAESTRO-NASH phase 3 trial, and understanding this data helps frame why TRICARE requires the specific documentation it does.

MAESTRO-NASH enrolled 966 patients with biopsy-confirmed NASH and liver fibrosis stages F1B through F3 across sites in the United States and internationally [1]. Patients were randomized to resmetirom 80 mg, resmetirom 100 mg, or placebo, taken once daily for 52 weeks. The trial used dual primary endpoints: NASH resolution with no worsening of fibrosis and at least a one-stage improvement in fibrosis with no worsening of the NAFLD Activity Score.

Results at 52 weeks showed that 25.9% of patients on resmetirom 100 mg achieved NASH resolution with no worsening of fibrosis, compared to 9.7% on placebo (P<0.001) [1]. For fibrosis improvement of at least one stage, 24.2% of the 100 mg group met this endpoint versus 14.2% on placebo (P<0.001). The lower 80 mg dose also showed statistically significant separation from placebo on both endpoints, though the effect sizes were smaller.

These results are what the FDA cited when granting accelerated approval. The approval is contingent on verification of clinical benefit in the ongoing MAESTRO-OUTCOMES trial, which is evaluating whether resmetirom reduces progression to cirrhosis, liver transplantation, and liver-related mortality. TRICARE's moderate prior authorization difficulty reflects this conditional approval status. The drug works, but long-term outcome data are still accumulating.

Safety data from MAESTRO-NASH showed that the most common adverse events were diarrhea (27% on 100 mg vs. 16% placebo) and nausea (20% vs. 12%) [1]. Serious adverse events occurred at similar rates across groups. The FDA label notes a risk of drug-induced liver injury and recommends hepatic function monitoring during treatment [5].

How to Appeal a TRICARE Denial for Rezdiffra

If TRICARE denies prior authorization for Rezdiffra, beneficiaries have a structured appeal pathway through the TRICARE ECHO contractor. The process has defined timelines and multiple levels.

The first step after receiving a denial letter is requesting a reconsideration from Express Scripts. This is an informal review that can sometimes resolve documentation gaps without a formal appeal. The prescriber submits additional clinical information directly to Express Scripts. If the reconsideration fails, the next step is a formal appeal.

TRICARE formal appeals follow this sequence: the beneficiary or provider files a written appeal within 90 days of the denial, the appeal goes to the TRICARE regional contractor for initial review, if denied again the case can be elevated to the TRICARE ECHO contractor for independent review, and final appeals can be directed to the Defense Health Agency (DHA).

For Rezdiffra specifically, successful appeals tend to include a letter of medical necessity from the treating hepatologist that references the MAESTRO-NASH data, the patient's individual fibrosis trajectory (showing progression over time), documentation of failed or contraindicated alternatives, and a statement addressing why the drug's benefit-risk profile favors treatment despite the accelerated approval status.

Dr. Zobair Younossi, chair of the Global NASH Council, has stated: "Patients with NASH and significant fibrosis face progressive liver damage, and timely pharmacologic intervention can alter their clinical trajectory when lifestyle measures alone prove insufficient" [6]. This type of specialist-endorsed framing strengthens appeal letters.

The timeline for a complete appeal cycle, from initial denial to final DHA decision, can stretch 60 to 120 days. Beneficiaries should not stop pursuing coverage during this period. Ask the prescriber's office whether a manufacturer bridge program can provide interim drug supply while the appeal is processed.

Cost and Financial Assistance Options

Rezdiffra carries a manufacturer list price of approximately $3,500 per month, which translates to roughly $42,000 annually. TRICARE beneficiaries face different cost-sharing depending on their specific plan.

TRICARE Prime enrollees who receive approval will pay the specialty-tier copay, which is generally $60 or less per fill for a 30-day supply at the mail-order pharmacy. TRICARE Select enrollees may face higher cost-sharing, particularly if using a retail pharmacy rather than mail order. Retired beneficiaries on TRICARE For Life with Medicare Part D as primary may find their costs determined by the Part D specialty tier, which can mean 25% to 33% coinsurance until the catastrophic coverage threshold is reached [7].

One important limitation: manufacturer copay assistance cards and savings programs from Madrigal Pharmaceuticals (Rezdiffra's maker) are generally not available to federal insurance beneficiaries. This includes TRICARE, Medicare Part D, Medicaid, and VA beneficiaries, per federal anti-kickback statute restrictions [8]. Beneficiaries covered under these programs cannot legally use manufacturer coupons to offset their out-of-pocket costs.

Alternative financial assistance options include the Madrigal Pharmaceuticals patient assistance program (PAP) for those who meet income eligibility criteria, independent charitable foundations that may cover MASH or liver disease medications, and the TRICARE Catastrophic Cap, which limits annual out-of-pocket spending to $1,000 for active-duty families and $3,500 for retiree families. Once the catastrophic cap is reached, TRICARE covers 100% of remaining costs for the benefit year [9].

MASH Diagnosis and Documentation Best Practices

Proper documentation of the MASH diagnosis is the single biggest factor in whether TRICARE approves Rezdiffra coverage. Incomplete clinical records cause more denials than actual coverage exclusions.

The gold standard for MASH diagnosis remains liver biopsy with histologic scoring using the NAFLD Activity Score (NAS) and fibrosis staging. A NAS of 4 or higher with fibrosis stage F2 or F3 is the clearest documentation for prior authorization purposes. The AASLD guidance published in Hepatology supports the use of liver biopsy as the reference standard for confirming steatohepatitis and staging fibrosis [3].

Noninvasive alternatives are increasingly accepted by TRICARE reviewers when biopsy is contraindicated or declined. FibroScan with a liver stiffness measurement between 8.0 and 13.0 kPa (consistent with F2-F3 fibrosis) combined with a controlled attenuation parameter (CAP) above 280 dB/m (consistent with significant steatosis) provides strong noninvasive evidence. The ELF test, with a score above 9.8 suggesting advanced fibrosis, is another validated option [10].

Include laboratory values showing elevated ALT (typically 1.5 to 5 times the upper limit of normal in active MASH), document the absence of significant alcohol use (standard threshold: fewer than 21 drinks per week for men, fewer than 14 for women), and rule out competing etiologies such as viral hepatitis, autoimmune hepatitis, and Wilson disease. This documentation package, submitted proactively with the prior authorization request, addresses the most common reviewer questions before they arise.

Comparing Rezdiffra to Other TRICARE-Covered MASH Treatments

No other FDA-approved drug specifically targets MASH, making Rezdiffra unique in the TRICARE formulary. Other medications used off-label for MASH have different coverage pathways.

Vitamin E (800 IU daily) is available over the counter and not subject to TRICARE pharmacy benefit management. It showed NASH resolution in 36% of patients in PIVENS but carries long-term safety concerns, including a possible increased risk of prostate cancer suggested by the SELECT trial (HR 1.17 to 99% CI 1.004-1.36, P=0.008) and hemorrhagic stroke [4, 11]. Pioglitazone, a generic thiazolidinedione, is covered on TRICARE's preferred formulary tier without prior authorization for its diabetes indication and costs under $15 per month. It improved NASH histology in PIVENS but causes weight gain (mean +4.7 kg) and is contraindicated in heart failure [4].

GLP-1 receptor agonists like semaglutide are covered by TRICARE with prior authorization for obesity and type 2 diabetes indications. In a phase 2 trial published in the New England Journal of Medicine, semaglutide 0.4 mg daily achieved NASH resolution in 59% of patients at 72 weeks versus 17% on placebo (P<0.001), though fibrosis improvement did not reach statistical significance [12]. TRICARE covers Wegovy and Zepbound with prior authorization and documented obesity-medicine criteria.

Resmetirom works through a different mechanism. It is a thyroid hormone receptor beta (THR-β) agonist that selectively activates hepatic THR-β to reduce liver fat, improve NASH histology, and lower atherogenic lipoproteins without systemic thyrotoxic effects [1]. This distinct mechanism means it can potentially be used alongside GLP-1 agonists for patients with both MASH and obesity, though combination data are limited.

Timeline and Practical Steps for TRICARE Beneficiaries

Getting Rezdiffra covered through TRICARE follows a predictable sequence when the documentation is prepared correctly. Here is the process from initial evaluation to first fill.

The prescribing provider confirms the MASH diagnosis with fibrosis staging (biopsy or validated noninvasive testing) and documents failed or contraindicated alternatives. The provider submits the prior authorization electronically through Express Scripts. Standard processing takes 5 to 10 business days. If approved, the prescription routes to the Express Scripts specialty pharmacy for mail-order dispensing. If denied, the provider submits a reconsideration with additional documentation within 30 days. A formal appeal follows if reconsideration fails.

Active-duty service members should coordinate through their military treatment facility (MTF) pharmacy, as some MTFs stock specialty medications directly and can bypass the Express Scripts prior authorization pathway entirely. The Defense Health Agency's Pharmacoeconomic Center (PEC) maintains a separate evaluation process for high-cost drugs at MTF pharmacies.

Dr. Arun Sanyal, a principal investigator on the MAESTRO-NASH trial, noted in the AASLD 2024 proceedings: "Resmetirom represents the first targeted pharmacotherapy for MASH, and access pathways need to reflect the progressive nature of fibrotic liver disease in patients who lack alternative FDA-approved options" [13]. This perspective supports the clinical urgency argument in prior authorization and appeal submissions.

Beneficiaries who anticipate needing Rezdiffra should request fibrosis staging documentation at their next hepatology visit, confirm their TRICARE plan type and pharmacy benefit structure, and ask their provider to initiate prior authorization proactively rather than waiting for the prescription to be rejected at the pharmacy counter.